Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegmolesatide vs ESAs on Ventricular Remodeling in Non-Dialysis CKD Renal Anemia
ChiCTR2600120693Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Mar 2026
- Modality
- PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of peglmolesatide in anemia of renal disease and cardiac remodeling (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: LVMI Modification (CMR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
peglmolesatide
03
Conditions
anemia of renal diseasecardiac remodeling
Beyond the preview
Go deeper on ChiCTR2600120693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120693.